1. Prior verified SARS-CoV-2 infection 2. Hypersensitivity reaction to chloroquine, hydroxychloroquine or 4-aminoquinolines 3. Electrocardiogram with QTc (Bazett’s formula) > 450 ms in males and 460 ms in females 4. Patients reliant on digoxin or amiodarone treatment 5. Pre-existing psoriasis 6. Any pre-existing maculopathy with vision reduction 7. Prior sensorineural hearing loss 8. Pre-existing severe liver insufficiency (spontaneous international normalized ratio >1.5 within the last year) 9. Pre-existing epileptic disease requiring anti-epileptic medication 10. Pregnancy or lactation 11. Insurmountable Language Barrier 12. Participation in other ongoing intervention trials investigating COVID19-related outcomes

1. Prior verified SARS-CoV-2 infection 2. Hypersensitivity reaction to chloroquine, hydroxychloroquine or 4-aminoquinolines 3. Electrocardiogram with QTc (Bazett’s formula) > 450 ms in males and 460 ms in females 4. Patients reliant on digoxin or amiodarone treatment 5. Pre-existing psoriasis 6. Any pre-existing maculopathy with vision reduction 7. Prior sensorineural hearing loss 8. Pre-existing severe liver insufficiency (spontaneous international normalized ratio >1.5 within the last year) 9. Pre-existing epileptic disease requiring anti-epileptic medication 10. Pregnancy or lactation 11. Insurmountable Language Barrier 12. Participation in other ongoing intervention trials investigating COVID19-related outcomes